Memberships and Associations:

Biography:

Our laboratory has a long standing interest in cancer immunotherapy and its impact on modulation of angiogenesis. We have been particularly interested in development of novel approaches to target the immunostimulatory and anti-angiogenic cytokine, interleukin-12, to vasculature within the tumor microenvironment. This work has evolved to include other approaches to suppress endothelial cell proliferation. Our current focus is on tyrosine kinase signaling pathways in malignant endothelial cells (i.e., canine hemangiosarcoma) in an effort to elucidate derangements and identify candidate aberrant kinases amenable to blockade by tyrosine kinase inhibitors. We are pursuing the potential to combine these various modalities with radiotherapy in tumor bearing animals. Other areas of interest include development of novel therapeutics for canine osteosarcoma and squamous cell carcinoma.